About: Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside?
Creator	Goffard, Anne Guery, Benoit Gosset, Philippe Bortolotti, Perinne Dessein, Rodrigue Dubucquoi, Sylvain Faure, Emmanuel Fournier, Clement Kipnis, Eric Martinez, Laura Mathieu, Daniel Poissy, Julien Titecat, Marie
source	Medline; PMC
abstract	One year after the occurrence of the first case of infection by the Middle East Respiratory Syndrome coronavirus (MERS-CoV) there is no clear consensus on the best treatment to propose. The World Health Organization, as well as several other national agencies, are still working on different clinical approaches to implement the most relevant treatment in MERS-CoV infection. We compared innate and adaptive immune responses of two patients infected with MERS-CoV to understand the underlying mechanisms involved in the response and propose potential therapeutic approaches. Broncho-alveolar lavage (BAL) of the first week and sera of the first month from the two patients were used in this study. Quantitative polymerase chain reaction (qRTPCR) was performed after extraction of RNA from BAL cells of MERS-CoV infected patients and control patients. BAL supernatants and sera were used to assess cytokines and chemokines secretion by enzyme-linked immunosorbent assay. The first patient died rapidly after 3 weeks in the intensive care unit, the second patient still recovers from infection. The patient with a poor outcome (patient 1), compared to patient 2, did not promote type-1 Interferon (IFN), and particularly IFNα, in response to double stranded RNA (dsRNA) from MERS-CoV. The absence of IFNα, known to promote antigen presentation in response to viruses, impairs the development of a robust antiviral adaptive Th-1 immune response. This response is mediated by IL-12 and IFNγ that decreases viral clearance; levels of both of these mediators were decreased in patient 1. Finally, we confirm previous in vitro findings that MERS-CoV can drive IL-17 production in humans. Host recognition of viral dsRNA determines outcome in the early stage of MERS-CoV infection. We highlight the critical role of IFNα in this initial stage to orchestrate a robust immune response and bring substantial arguments for the indication of early IFNα treatment during MERS-CoV infection.
has issue date	2014-02-14(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0088716
bibo:pmid	24551142
has license	cc-by
sha1sum (hex)	dc38fa3321df5137294140ffe1a358399befb500
schema:url	https://doi.org/10.1371/journal.pone.0088716
resource representing a document's title	Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside?
has PubMed Central identifier	PMC3925152
has PubMed identifier	24551142
schema:publication	PLoS One
resource representing a document's body	covid:dc38fa3321df5137294140ffe1a358399befb500#body_text
is schema:about of	named entity 'INFECTED' named entity 'substantial' named entity 'robust' named entity 'viruses' named entity 'RNA' named entity 'MERS-CoV' named entity 'chemokines' named entity 'Middle East Respiratory Syndrome coronavirus' named entity 'initial' named entity 'patients' named entity 'compared' named entity 'infection' named entity 'early' named entity 'One' named entity 'week' named entity 'CONFIRM' named entity 'RESPONSE TO VIRUSES' named entity 'RECOGNITION' named entity 'PREVIOUS' named entity 'TREATMENT' named entity 'OUTCOME' named entity 'RESPONSE TO' named entity 'THESE' named entity 'TH-1' named entity 'INDICATION OF' named entity 'MONTH' named entity 'EARLY STAGE' named entity 'VIRAL' named entity 'MECHANISMS' named entity 'COMPARED' named entity 'NATIONAL' named entity 'DEVELOPMENT' named entity 'RNA' named entity 'SERA' named entity 'WEEK' named entity 'UNDERSTAND' named entity 'DECREASES' named entity 'ARGUMENTS' named entity 'QUANTITATIVE POLYMERASE CHAIN REACTION' named entity 'CONSENSUS' named entity 'HUMANS' named entity 'BAL' named entity 'INTERFERON ' named entity 'DID' named entity 'ONE YEAR' named entity 'USED' named entity 'CLINICAL' named entity 'IN VITRO' named entity 'MEDIATED' named entity 'STUDY' named entity 'LEVELS' named entity 'ASSESS' named entity 'IMPAIRS' named entity 'CELLS' named entity '3 WEEKS' named entity 'IMMUNE RESPONSE' named entity 'WORLD HEALTH ORGANIZATION' named entity 'ADAPTIVE IMMUNE RESPONSES' named entity 'DSRNA' named entity 'RECOVERS' named entity 'CASE' named entity 'DRIVE' named entity 'CYTOKINES' named entity 'EARLY' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' named entity 'KNOWN' named entity 'RESPONSE' covid:arg/dc38fa3321df5137294140ffe1a358399befb500 named entity 'EXTRACTION'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software